The Oxford Handbook of the Economics of the Biopharmaceutical Industry

Note moyenne 0
( 0 avis fournis par GoodReads )
9780199742998: The Oxford Handbook of the Economics of the Biopharmaceutical Industry

The biopharmaceutical industry has been a major driver of technological change in health care, producing unprecedented benefits for patients, cost challenges for payers, and profits for shareholders. As consumers and companies benefit from access to new drugs, policymakers around the globe seek mechanisms to control prices and expenditures commensurate with value. More recently the 1990s productivity boom of new products has turned into a productivity bust, with fewer and more modest innovations, and flat or declining revenues for innovative firms as generics replace their former blockbuster products. This timely volume examines the economics of the biopharmaceutical industry, with 18 chapters by leading academic health economists. Part one examines the economics of biopharmaceutical innovation including determinants of the costs and returns to new drug development; how capital markets finance R&D and how costs of financing the biopharmaceutical industry compare to financing costs for other industries; the effects of safety and efficacy regulation by the Food and Drug Administration (FDA) and of price and reimbursement regulation on incentives for innovation; and the role of patents and regulatory exclusivities. Part two examines the market for biopharmaceuticals with chapters on prices and reimbursement in the US, the EU, and other industrialized countries, and in developing countries. It looks at the optimal design of insurance for drugs and the effects of cost sharing on spending and on health outcomes; how to measure the value of pharmaceuticals using pharmacoeconomics, including theory, practical challenges, and policy issues; how to measure pharmaceutical price growth over time and recent evidence; empirical evidence on the value of pharmaceuticals in terms of health outcomes; promotion of pharmaceuticals to physicians and consumers; the economics of vaccines; and a review of the evidence on effects of mergers, acquisitions and alliances. Each chapter summariz

Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.

Biographie de l'auteur :

Patricia Danzon is Celia Moh Professor at The Wharton School, University of Pennsylvania, where she is former Chair of the Health Care Systems Department, and Professor of Insurance and Risk Management. She received a B.A. from Oxford University and a Ph.D. in Economics from the University of Chicago. She is an internationally recognized expert on health economics and policy, and on the biopharmaceutical industry in particular. She is a member of the Institute of Medicine and a Research Associate of the National Bureau of Economic Research. She has served as a consultant to many governmental agencies, NGOs and private corporations in the US and internationally. Sean Nicholson is Associate Professor of Policy Analysis and Management (PAM) at Cornell University and a Faculty Research Fellow at the National Bureau of Economic Research. He received a B.A. from Dartmouth College in 1986 and a Ph.D. in economics from the University of Wisconsin-Madison in 1997. He is a recognized expert in health economics, particularly with regard to the biopharmaceutical industry and the medical workforce.

Revue de presse :

I was certainly impressed by the breadth of the book... the various authors do a good job in developing the concepts in a readily understood fashion. ( John R. Cook, Journal of Biopharmaceutical Statistics)

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.

Meilleurs résultats de recherche sur AbeBooks

1.

Patricia M. Danzon, Sean Nicholson
Edité par Oxford University Press
ISBN 10 : 0199742995 ISBN 13 : 9780199742998
Neuf(s) Quantité : 12
Vendeur
INDOO
(Avenel, NJ, Etats-Unis)
Evaluation vendeur
[?]

Description du livre Oxford University Press. État : New. Brand New. N° de réf. du libraire 0199742995

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 128,31
Autre devise

Ajouter au panier

Frais de port : EUR 3,25
Vers Etats-Unis
Destinations, frais et délais

2.

Edité par Oxford University Press Inc, United States (2012)
ISBN 10 : 0199742995 ISBN 13 : 9780199742998
Neuf(s) Couverture rigide Quantité : 1
Vendeur
The Book Depository US
(London, Royaume-Uni)
Evaluation vendeur
[?]

Description du livre Oxford University Press Inc, United States, 2012. Hardback. État : New. 257 x 178 mm. Language: English . Brand New Book. The biopharmaceutical industry has been a major driver of technological change in health care, producing unprecedented benefits for patients, cost challenges for payers, and profits for shareholders. As consumers and companies benefit from access to new drugs, policymakers around the globe seek mechanisms to control prices and expenditures commensurate with value. More recently the 1990s productivity boom of new products has turned into a productivity bust, with fewer and more modest innovations, and flat or declining revenues for innovative firms as generics replace their former blockbuster products. This timely volume examines the economics of the biopharmaceutical industry, with 18 chapters by leading academic health economists. Part one examines the economics of biopharmaceutical innovation including determinants of the costs and returns to new drug development; how capital markets finance RD and how costs of financing the biopharmaceutical industry compare to financing costs for other industries; the effects of safety and efficacy regulation by the Food and Drug Administration (FDA) and of price and reimbursement regulation on incentives for innovation; and the role of patents and regulatory exclusivities. Part two examines the market for biopharmaceuticals with chapters on prices and reimbursement in the US, the EU, and other industrialized countries, and in developing countries. It looks at the optimal design of insurance for drugs and the effects of cost sharing on spending and on health outcomes; how to measure the value of pharmaceuticals using pharmacoeconomics, including theory, practical challenges, and policy issues; how to measure pharmaceutical price growth over time and recent evidence; empirical evidence on the value of pharmaceuticals in terms of health outcomes; promotion of pharmaceuticals to physicians and consumers; the economics of vaccines; and a review of the evidence on effects of mergers, acquisitions and alliances. Each chapter summarizes the latest insights from theory and recent empirical evidence, and outlines important unanswered questions and areas for future research. Based on solid economics, it is nevertheless written in terms accessible to the general reader. The book is thus recommended reading for academic economists and non-economists, and for those in industry and policy who wish to understand the economics of this fascinating industry. N° de réf. du libraire KNV9780199742998

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 138,85
Autre devise

Ajouter au panier

Frais de port : Gratuit
De Royaume-Uni vers Etats-Unis
Destinations, frais et délais

3.

Nicholson, Sean (edt); Danzon, Patricia M. (edt)
ISBN 10 : 0199742995 ISBN 13 : 9780199742998
Neuf(s) Quantité : 5
Vendeur
GreatBookPrices
(Columbia, MD, Etats-Unis)
Evaluation vendeur
[?]

Description du livre État : New. N° de réf. du libraire 18267568-n

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 138,57
Autre devise

Ajouter au panier

Frais de port : EUR 2,45
Vers Etats-Unis
Destinations, frais et délais

4.

Edité par Oxford University Press Inc, United States (2012)
ISBN 10 : 0199742995 ISBN 13 : 9780199742998
Neuf(s) Couverture rigide Quantité : 1
Vendeur
The Book Depository
(London, Royaume-Uni)
Evaluation vendeur
[?]

Description du livre Oxford University Press Inc, United States, 2012. Hardback. État : New. 257 x 178 mm. Language: English . Brand New Book. The biopharmaceutical industry has been a major driver of technological change in health care, producing unprecedented benefits for patients, cost challenges for payers, and profits for shareholders. As consumers and companies benefit from access to new drugs, policymakers around the globe seek mechanisms to control prices and expenditures commensurate with value. More recently the 1990s productivity boom of new products has turned into a productivity bust, with fewer and more modest innovations, and flat or declining revenues for innovative firms as generics replace their former blockbuster products. This timely volume examines the economics of the biopharmaceutical industry, with 18 chapters by leading academic health economists. Part one examines the economics of biopharmaceutical innovation including determinants of the costs and returns to new drug development; how capital markets finance RD and how costs of financing the biopharmaceutical industry compare to financing costs for other industries; the effects of safety and efficacy regulation by the Food and Drug Administration (FDA) and of price and reimbursement regulation on incentives for innovation; and the role of patents and regulatory exclusivities. Part two examines the market for biopharmaceuticals with chapters on prices and reimbursement in the US, the EU, and other industrialized countries, and in developing countries. It looks at the optimal design of insurance for drugs and the effects of cost sharing on spending and on health outcomes; how to measure the value of pharmaceuticals using pharmacoeconomics, including theory, practical challenges, and policy issues; how to measure pharmaceutical price growth over time and recent evidence; empirical evidence on the value of pharmaceuticals in terms of health outcomes; promotion of pharmaceuticals to physicians and consumers; the economics of vaccines; and a review of the evidence on effects of mergers, acquisitions and alliances. Each chapter summarizes the latest insights from theory and recent empirical evidence, and outlines important unanswered questions and areas for future research. Based on solid economics, it is nevertheless written in terms accessible to the general reader. The book is thus recommended reading for academic economists and non-economists, and for those in industry and policy who wish to understand the economics of this fascinating industry. N° de réf. du libraire KNV9780199742998

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 145,38
Autre devise

Ajouter au panier

Frais de port : Gratuit
De Royaume-Uni vers Etats-Unis
Destinations, frais et délais

5.

Patricia M. Danzon
Edité par Oxford University Press Jun 2012 (2012)
ISBN 10 : 0199742995 ISBN 13 : 9780199742998
Neuf(s) Quantité : 1
Vendeur
Evaluation vendeur
[?]

Description du livre Oxford University Press Jun 2012, 2012. Buch. État : Neu. 255x180x36 mm. Neuware - The biopharmaceutical industry has been a major driver of technological change in health care, producing unprecedented benefits for patients, cost challenges for payers, and profits for shareholders. As consumers and companies benefit from access to new drugs, policymakers around the globe seek mechanisms to control prices and expenditures commensurate with value. More recently the 1990s productivity boom of new products has turned into a productivity bust, with fewer and more modest innovations, and flat or declining revenues for innovative firms as generics replace their former blockbuster products. This timely volume examines the economics of the biopharmaceutical industry, with 18 chapters by leading academic health economists. Part one examines the economics of biopharmaceutical innovation including determinants of the costs and returns to new drug development; how capital markets finance R&D and how costs of financing the biopharmaceutical industry compare to financing costs for other industries; the effects of safety and efficacy regulation by the Food and Drug Administration (FDA) and of price and reimbursement regulation on incentives for innovation; and the role of patents and regulatory exclusivities. Part two examines the market for biopharmaceuticals with chapters on prices and reimbursement in the US, the EU, and other industrialized countries, and in developing countries. It looks at the optimal design of insurance for drugs and the effects of cost sharing on spending and on health outcomes; how to measure the value of pharmaceuticals using pharmacoeconomics, including theory, practical challenges, and policy issues; how to measure pharmaceutical price growth over time and recent evidence; empirical evidence on the value of pharmaceuticals in terms of health outcomes; promotion of pharmaceuticals to physicians and consumers; the economics of vaccines; and a review of the evidence on effects of mergers, acquisitions and alliances. Each chapter summarizes the latest insights from theory and recent empirical evidence, and outlines important unanswered questions and areas for future research. Based on solid economics, it is nevertheless written in terms accessible to the general reader. The book is thus recommended reading for academic economists and non-economists, and for those in industry and policy who wish to understand the economics of this fascinating industry. 624 pp. Englisch. N° de réf. du libraire 9780199742998

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 149,55
Autre devise

Ajouter au panier

Frais de port : EUR 12
De Allemagne vers Etats-Unis
Destinations, frais et délais

6.

Patricia M. Danzon
Edité par Oxford University Press Jun 2012 (2012)
ISBN 10 : 0199742995 ISBN 13 : 9780199742998
Neuf(s) Quantité : 1
Vendeur
Rheinberg-Buch
(Bergisch Gladbach, Allemagne)
Evaluation vendeur
[?]

Description du livre Oxford University Press Jun 2012, 2012. Buch. État : Neu. 255x180x36 mm. Neuware - The biopharmaceutical industry has been a major driver of technological change in health care, producing unprecedented benefits for patients, cost challenges for payers, and profits for shareholders. As consumers and companies benefit from access to new drugs, policymakers around the globe seek mechanisms to control prices and expenditures commensurate with value. More recently the 1990s productivity boom of new products has turned into a productivity bust, with fewer and more modest innovations, and flat or declining revenues for innovative firms as generics replace their former blockbuster products. This timely volume examines the economics of the biopharmaceutical industry, with 18 chapters by leading academic health economists. Part one examines the economics of biopharmaceutical innovation including determinants of the costs and returns to new drug development; how capital markets finance R&D and how costs of financing the biopharmaceutical industry compare to financing costs for other industries; the effects of safety and efficacy regulation by the Food and Drug Administration (FDA) and of price and reimbursement regulation on incentives for innovation; and the role of patents and regulatory exclusivities. Part two examines the market for biopharmaceuticals with chapters on prices and reimbursement in the US, the EU, and other industrialized countries, and in developing countries. It looks at the optimal design of insurance for drugs and the effects of cost sharing on spending and on health outcomes; how to measure the value of pharmaceuticals using pharmacoeconomics, including theory, practical challenges, and policy issues; how to measure pharmaceutical price growth over time and recent evidence; empirical evidence on the value of pharmaceuticals in terms of health outcomes; promotion of pharmaceuticals to physicians and consumers; the economics of vaccines; and a review of the evidence on effects of mergers, acquisitions and alliances. Each chapter summarizes the latest insights from theory and recent empirical evidence, and outlines important unanswered questions and areas for future research. Based on solid economics, it is nevertheless written in terms accessible to the general reader. The book is thus recommended reading for academic economists and non-economists, and for those in industry and policy who wish to understand the economics of this fascinating industry. 624 pp. Englisch. N° de réf. du libraire 9780199742998

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 149,55
Autre devise

Ajouter au panier

Frais de port : EUR 17,13
De Allemagne vers Etats-Unis
Destinations, frais et délais

7.

Patricia M. Danzon
Edité par Oxford University Press Jun 2012 (2012)
ISBN 10 : 0199742995 ISBN 13 : 9780199742998
Neuf(s) Quantité : 1
Vendeur
Agrios-Buch
(Bergisch Gladbach, Allemagne)
Evaluation vendeur
[?]

Description du livre Oxford University Press Jun 2012, 2012. Buch. État : Neu. 255x180x36 mm. Neuware - The biopharmaceutical industry has been a major driver of technological change in health care, producing unprecedented benefits for patients, cost challenges for payers, and profits for shareholders. As consumers and companies benefit from access to new drugs, policymakers around the globe seek mechanisms to control prices and expenditures commensurate with value. More recently the 1990s productivity boom of new products has turned into a productivity bust, with fewer and more modest innovations, and flat or declining revenues for innovative firms as generics replace their former blockbuster products. This timely volume examines the economics of the biopharmaceutical industry, with 18 chapters by leading academic health economists. Part one examines the economics of biopharmaceutical innovation including determinants of the costs and returns to new drug development; how capital markets finance R&D and how costs of financing the biopharmaceutical industry compare to financing costs for other industries; the effects of safety and efficacy regulation by the Food and Drug Administration (FDA) and of price and reimbursement regulation on incentives for innovation; and the role of patents and regulatory exclusivities. Part two examines the market for biopharmaceuticals with chapters on prices and reimbursement in the US, the EU, and other industrialized countries, and in developing countries. It looks at the optimal design of insurance for drugs and the effects of cost sharing on spending and on health outcomes; how to measure the value of pharmaceuticals using pharmacoeconomics, including theory, practical challenges, and policy issues; how to measure pharmaceutical price growth over time and recent evidence; empirical evidence on the value of pharmaceuticals in terms of health outcomes; promotion of pharmaceuticals to physicians and consumers; the economics of vaccines; and a review of the evidence on effects of mergers, acquisitions and alliances. Each chapter summarizes the latest insights from theory and recent empirical evidence, and outlines important unanswered questions and areas for future research. Based on solid economics, it is nevertheless written in terms accessible to the general reader. The book is thus recommended reading for academic economists and non-economists, and for those in industry and policy who wish to understand the economics of this fascinating industry. 624 pp. Englisch. N° de réf. du libraire 9780199742998

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 149,55
Autre devise

Ajouter au panier

Frais de port : EUR 17,13
De Allemagne vers Etats-Unis
Destinations, frais et délais

8.

Edité par Oxford University Press (2012)
ISBN 10 : 0199742995 ISBN 13 : 9780199742998
Neuf(s) Couverture rigide Quantité : 1
Vendeur
Book Deals
(Lewiston, NY, Etats-Unis)
Evaluation vendeur
[?]

Description du livre Oxford University Press, 2012. État : New. Brand New, Unread Copy in Perfect Condition. A+ Customer Service! Summary: This volume comprises 18 chapters by leading academics on the economics of the biopharmaceutical industry. Part one examines economic determinants of biopharmaceutical R&D including financing, regulation, and patents. Part two addresses major issues in pharmaceutical markets including pricing, price regulation, and promotion; insurance coverage and effects of patient cost-sharing; the health value of pharmaceuticals; and the endemic use of mergers, acquisitions, andalliances. N° de réf. du libraire ABE_book_new_0199742995

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 171
Autre devise

Ajouter au panier

Frais de port : Gratuit
Vers Etats-Unis
Destinations, frais et délais

9.

Patricia M. Danzon
Edité par Oxford University Press Jun 2012 (2012)
ISBN 10 : 0199742995 ISBN 13 : 9780199742998
Neuf(s) Quantité : 1
Vendeur
AHA-BUCH GmbH
(Einbeck, Allemagne)
Evaluation vendeur
[?]

Description du livre Oxford University Press Jun 2012, 2012. Buch. État : Neu. 255x180x36 mm. Neuware - The biopharmaceutical industry has been a major driver of technological change in health care, producing unprecedented benefits for patients, cost challenges for payers, and profits for shareholders. As consumers and companies benefit from access to new drugs, policymakers around the globe seek mechanisms to control prices and expenditures commensurate with value. More recently the 1990s productivity boom of new products has turned into a productivity bust, with fewer and more modest innovations, and flat or declining revenues for innovative firms as generics replace their former blockbuster products. This timely volume examines the economics of the biopharmaceutical industry, with 18 chapters by leading academic health economists. Part one examines the economics of biopharmaceutical innovation including determinants of the costs and returns to new drug development; how capital markets finance R&D and how costs of financing the biopharmaceutical industry compare to financing costs for other industries; the effects of safety and efficacy regulation by the Food and Drug Administration (FDA) and of price and reimbursement regulation on incentives for innovation; and the role of patents and regulatory exclusivities. Part two examines the market for biopharmaceuticals with chapters on prices and reimbursement in the US, the EU, and other industrialized countries, and in developing countries. It looks at the optimal design of insurance for drugs and the effects of cost sharing on spending and on health outcomes; how to measure the value of pharmaceuticals using pharmacoeconomics, including theory, practical challenges, and policy issues; how to measure pharmaceutical price growth over time and recent evidence; empirical evidence on the value of pharmaceuticals in terms of health outcomes; promotion of pharmaceuticals to physicians and consumers; the economics of vaccines; and a review of the evidence on effects of mergers, acquisitions and alliances. Each chapter summarizes the latest insights from theory and recent empirical evidence, and outlines important unanswered questions and areas for future research. Based on solid economics, it is nevertheless written in terms accessible to the general reader. The book is thus recommended reading for academic economists and non-economists, and for those in industry and policy who wish to understand the economics of this fascinating industry. 624 pp. Englisch. N° de réf. du libraire 9780199742998

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 149,55
Autre devise

Ajouter au panier

Frais de port : EUR 29,50
De Allemagne vers Etats-Unis
Destinations, frais et délais

10.

Edité par OUP USA (2012)
ISBN 10 : 0199742995 ISBN 13 : 9780199742998
Neuf(s) Couverture rigide Quantité : 1
Vendeur
Revaluation Books
(Exeter, Royaume-Uni)
Evaluation vendeur
[?]

Description du livre OUP USA, 2012. Hardcover. État : Brand New. 1st edition. 624 pages. 9.80x6.80x1.10 inches. In Stock. N° de réf. du libraire zk0199742995

Plus d'informations sur ce vendeur | Poser une question au libraire

Acheter neuf
EUR 196,58
Autre devise

Ajouter au panier

Frais de port : EUR 7,04
De Royaume-Uni vers Etats-Unis
Destinations, frais et délais

autres exemplaires de ce livre sont disponibles

Afficher tous les résultats pour ce livre